Erasca Faces Securities Fraud Class Action Lawsuit
Law firm Berger Montague has filed a class action lawsuit against Erasca, Inc. for investors who purchased stock between January 2025 and April 2026. The suit alleges the company made misrepresentations about its drug candidate ERAS-0015.
National plaintiffs' law firm Berger Montague has initiated a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS). The suit is filed on behalf of investors who acquired Erasca common stock from January 14, 2025, through April 26, 2026.
The complaint alleges that Erasca and its management made repeated positive statements touting ERAS-0015, a potential cancer therapy, as "best-in-class." These statements allegedly included purportedly superior preclinical results compared to a competing drug candidate from Revolution Medicines, while failing to disclose that these comparisons were improper and exposed the company to patent and trade secret disputes.
The company's stock price fell over 45%, or $9.90 per share, following disclosures on April 27, 2026. On that date, Revolution Medicines accused Erasca of patent infringement and trade secret misappropriation. Erasca also released preliminary clinical data showing a patient death and acknowledged that comparisons of ERAS-0015 were based on limited cross-study analyses, not head-to-head trials.
Investors who purchased Erasca securities during the specified period have until August 10, 2026, to seek appointment as lead plaintiff. Berger Montague is encouraging affected investors to contact them for more information regarding their rights.